ELECTRICAL DEVICES AND ANTI-SCARRING AGENTS

• US 20100268288A1
• Filed: 02/10/2010
• Published: 10/21/2010
• Est. Priority Date: 11/20/2003
• Status: Abandoned Application

• Current Assignee: Angiotech Pharmaceuticals Incorporated
• Original Assignee: Angiotech Pharmaceuticals Incorporated
• Inventors: Hunter, William L., Toleikis, Philip M., Gravett, David M., Maiti, Arpita
• Application Number:
  US12/703,679
• Publication Number:
  US 20100268288A1
• Time in Patent Office: Days
• US Class Current: 607/3
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/432 Inhibitors, antagonists A61L2300/402 - A61L2300/43 take precedence
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 27/3641 characterised by the site of application in the body materials for artificial blood vessels A61L27/507; materials for use in artificial skin A61L27/60
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61N 1/05 for implantation or insertion into the body, e.g. heart electrode A61N1/06 takes precedence
• CPC Class Codes: A61N 1/372 Arrangements in connection with the implantation of stimulators
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 41/00 Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system

Abstract

Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

Claims

1. A medical device, comprising an electrical device and an anti-scarring agent or a composition comprising an anti-scarring agent, wherein the anti-scarring agent inhibits scarring between the medical device and the host into which the medical device is implanted.

2. The medical device of claim 1, wherein the anti-scarring agent is a sirolimus.

3. The medical device of claim 1, wherein the anti-scarring agent is everolimus, tacrolimus, pimecrolimus or biolimus.

4. The medical device of claim 1, wherein the electrical device is a neurostimulator.

5. The medical device of claim 4, wherein the neurostimulator is a neurostimulator for treating chronic pain, a neurostimulator for treating Parkinson'"'"'s disease, a sacral nerve stimulator, a gastric nerve stimulator, or a bone growth stimulator.

6. The medical device of claim 4, wherein the electrical device is a vagal nerve stimulator.

7. The medical device of claim 6, wherein the vagal nerve stimulator is a vagal nerve stimulator for treating epilepsy or a vagal nerve stimulator for treating arrhythmia.

8. The medical device of claim 1, wherein the electrical device is a cochlear implant, a cardiac rhythm management device, a cardiac pacemaker, or an implantable cardioverter defibrillator system.

9. The medical device of claim 1, wherein the electric device is a pacemaker lead.

10. The medical device of claim 1, further comprising a second pharmaceutically active agent.

11. The medical device of claim 10, wherein the second pharmaceutically active agent is an agent that inhibits infection.

12. The medical device of claim 1, wherein the composition comprising an anti-scarring agent comprises a polymer.

13. A method for inhibiting scarring, comprising placing an electrical device and an anti-scarring agent or a composition comprising an anti-scarring agent into an animal host, wherein the anti-scarring agent inhibits scarring between the electrical device and the animal host.

14. The method of claim 13, wherein the electrical device is a neurostimulator, a cochlear implant, a cardiac rhythm management device, a cardiac pacemaker, or an implantable cardioverter defibrillator system, or a pacemaker lead.

15. The method of claim 14, wherein the neurostimulator is a neurostimulator for treating chronic pain, a neurostimulator for treating Parkinson'"'"'s disease, a sacral nerve stimulator, a gastric nerve stimulator, a bone growth stimulator, a vagal nerve stimulator.

16. The method of claim 13, wherein the anti-scarring agent is sirolimus, everolimus, tacrolimus, pimecrolimus or biolimus.

17. A method for making a medical device, comprising combining an electrical device with an anti-scarring agent or a composition comprising an anti-scarring agent, wherein the anti-scarring agent inhibits scarring between the electrical device and a host into which the electrical device is implanted.

18. The method of claim 17, wherein the electrical device is a neurostimulator, a cochlear implant, a cardiac rhythm management device, a cardiac pacemaker, or an implantable cardioverter defibrillator system, or a pacemaker lead.

19. The method of claim 18, wherein the neurostimulator is a neurostimulator for treating chronic pain, a neurostimulator for treating Parkinson'"'"'s disease, a sacral nerve stimulator, a gastric nerve stimulator, a bone growth stimulator, or a vagal nerve stimulator.

20. The method of claim 17, wherein the anti-scarring agent is sirolimus, everolimus, tacrolimus, pimecrolimus or biolimus.